Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers.
about
Challenges in using opioids to treat pain in persons with substance use disordersNarcotic analgesic utilization amongst injured workers: using concept mapping to understand current issues from the perspectives of physicians and pharmacists.Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations.Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.Designing opioids that deter abuseResearch design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations.Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.Physical pain, common psychiatric and substance use disorders, and the non-medical use of prescription analgesics in the United States.Can abuse deterrent formulations make a difference? Expectation and speculation.Oxycodone combined with opioid receptor antagonists: efficacy and safety.Validity testing of patient objections to acceptance of tamper-resistant opioid formulations.Designing a tool allowing for a standardized assessment of resistance to drug diversion.Abuse-deterrent formulations of opioid analgesics.The implications of tamper-resistant formulations for opioid rotation.Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.Lignes directrices canadiennes sur l’utilisation sécuritaire et efficace des opioïdes pour la douleur chronique non cancéreuse: Résumé clinique pour les médecins de famille. Partie 2: populations particulières.Oxycodone extended-release using gel-cap technology to resist alteration and abuse for the treatment of moderate-to-severe pain.
P2860
Q33553159-47BD52E0-3994-4536-AAE2-6A99EFBD5E1AQ34052430-F1400497-536F-43FF-9074-704AFE869423Q35548503-058DCFE7-D9F0-428E-BAD5-7743E8E8DE36Q36399627-7100FF07-8F8E-4CFB-9636-ADEAEC8D091BQ36415568-B38B3B50-E7DD-4514-A99C-ADDB2E993137Q36742039-17CEBF9B-8B2E-415E-A901-A5E590496024Q36845718-15F34B57-298F-48C4-9CD6-23846A1617D6Q37109399-4BBAAC39-0C52-4E73-B3B6-DF1EC1F72262Q37223480-E317196D-AC3A-4491-A4AC-2F475FC84EC4Q38093671-83967E86-F5B4-419E-8272-9CA979D58965Q40844854-39D09535-C972-4DCF-BCC8-06379B44C24DQ43317466-7B4DA457-27B8-4521-8A1D-939F936BBF80Q43976503-65684AB2-5AE0-4A4D-BA0E-D5AE4D453357Q44336529-60422541-6E00-4B50-BD98-6C4893DFF322Q44340245-8D355BE0-8A42-49F4-BE47-B7AAE2106B55Q44348014-9DF7A8AF-7313-4866-A4E2-100E36E97235Q45871173-47514ED1-6D15-429C-BBEC-E98BB5C8A3DDQ48114787-6F419FCF-0F36-4804-9FC7-29DC931C64FE
P2860
Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Development and validation of ...... products to potential abusers
@nl
Development and validation of ...... products to potential abusers.
@ast
Development and validation of ...... products to potential abusers.
@en
type
label
Development and validation of ...... products to potential abusers
@nl
Development and validation of ...... products to potential abusers.
@ast
Development and validation of ...... products to potential abusers.
@en
prefLabel
Development and validation of ...... products to potential abusers
@nl
Development and validation of ...... products to potential abusers.
@ast
Development and validation of ...... products to potential abusers.
@en
P2093
P2860
P356
P1476
Development and validation of ...... products to potential abusers.
@en
P2093
Christine Benoit
Cynthia McCormick
Kathrine C Fernandez
Nathaniel Katz
Simon H Budman
Synne Wing Venuti
P2860
P2888
P356
10.1186/1477-7517-3-5
P407
P577
2006-02-02T00:00:00Z
P5875
P6179
1031937170